This is the limited version of the Novacea company profile: Join LinkedIn or Sign In to see more information.
Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate includes Asentar, which is in Phase III clinical trials for the treatment of androgen-independent prostate cancer; and AQ4N, which is in Phase 1/2 clinical trial for the treatment of glioblastoma multiforme. The company has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; Schering-Plough Corp.; and Pierre Fabre Medicament. The company, formerly known as D-Novo Therapeutics, Inc., was founded in 2001. Novacea is headquartered in South San Francisco, California.
Your Connections to Novacea
Popular Profiles at Novacea
601 Gateway Boulevard
Suite 800
South San Francisco, CA
94080
United States
Phone: 650-228-1800
Estimated based on LinkedIn Data
Career path for Novacea employees
In partnership with 
Send feedback on BusinessWeek/CapIQ content to linkedinissues@capitaliq.com. Copyright © 2009 Capital IQ.
This LinkedIn Company Profile was created by LinkedIn and is about Novacea. This page is not endorsed by or affiliated with Novacea. For questions regarding LinkedIn Company Profiles, contact us.
Interactive Data Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions
| 